These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 23204401)

  • 41. Proof of concept of a new plasma complement Factor H from waste plasma fraction.
    Mori F; Pascali G; Berra S; Lazzarotti A; Panetta D; Rocchiccioli S; Ceccherini E; Norelli F; Morlando A; Donadelli R; Clivio A; Farina C; Noris M; Salvadori PA; Remuzzi G
    Front Immunol; 2024; 15():1334151. PubMed ID: 38919628
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Causes of alternative pathway dysregulation in dense deposit disease.
    Zhang Y; Meyer NC; Wang K; Nishimura C; Frees K; Jones M; Katz LM; Sethi S; Smith RJ
    Clin J Am Soc Nephrol; 2012 Feb; 7(2):265-74. PubMed ID: 22223606
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Novel Assays to Distinguish Between Properdin-Dependent and Properdin-Independent C3 Nephritic Factors Provide Insight Into Properdin-Inhibiting Therapy.
    Michels MAHM; van de Kar NCAJ; van den Bos RM; van der Velden TJAM; van Kraaij SAW; Sarlea SA; Gracchi V; Oosterveld MJS; Volokhina EB; van den Heuvel LPWJ
    Front Immunol; 2019; 10():1350. PubMed ID: 31263464
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Complement receptor 3 mediates renal protection in experimental C3 glomerulopathy.
    Barbour TD; Ling GS; Ruseva MM; Fossati-Jimack L; Cook HT; Botto M; Pickering MC
    Kidney Int; 2016 Apr; 89(4):823-32. PubMed ID: 26924054
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pathology after eculizumab in dense deposit disease and C3 GN.
    Herlitz LC; Bomback AS; Markowitz GS; Stokes MB; Smith RN; Colvin RB; Appel GB; D'Agati VD
    J Am Soc Nephrol; 2012 Jul; 23(7):1229-37. PubMed ID: 22677550
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A properdin dependent nephritic factor slowly activating C3, C5, and C9 in membranoproliferative glomerulonephritis, types I and III.
    Clardy CW; Forristal J; Strife CF; West CD
    Clin Immunol Immunopathol; 1989 Mar; 50(3):333-47. PubMed ID: 2917424
    [TBL] [Abstract][Full Text] [Related]  

  • 47. C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up.
    Sethi S; Fervenza FC; Zhang Y; Zand L; Vrana JA; Nasr SH; Theis JD; Dogan A; Smith RJ
    Kidney Int; 2012 Aug; 82(4):465-73. PubMed ID: 22673887
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Two types of C3 nephritic factor: properdin-dependent C3NeF and properdin-independent C3NeF.
    Tanuma Y; Ohi H; Hatano M
    Clin Immunol Immunopathol; 1990 Aug; 56(2):226-38. PubMed ID: 2143128
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Characterization of C3 in C3 glomerulopathy.
    Sethi S; Vrana JA; Fervenza FC; Theis JD; Sethi A; Kurtin PJ; Zhang Y; Smith RJH
    Nephrol Dial Transplant; 2017 Mar; 32(3):459-465. PubMed ID: 27507892
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Distinct roles for the complement regulators factor H and Crry in protection of the kidney from injury.
    Laskowski J; Renner B; Le Quintrec M; Panzer S; Hannan JP; Ljubanovic D; Ruseva MM; Borza DB; Antonioli AH; Pickering MC; Holers VM; Thurman JM
    Kidney Int; 2016 Jul; 90(1):109-22. PubMed ID: 27165610
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Heterogeneous pattern of renal disease associated with homozygous factor H deficiency.
    Servais A; Noël LH; Dragon-Durey MA; Gübler MC; Rémy P; Buob D; Cordonnier C; Makdassi R; Jaber W; Boulanger E; Lesavre P; Frémeaux-Bacchi V
    Hum Pathol; 2011 Sep; 42(9):1305-11. PubMed ID: 21396679
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Modeling C3 glomerulopathies: C3 convertase regulation on an extracellular matrix surface.
    Pisarenka S; Meyer NC; Xiao X; Goodfellow R; Nester CM; Zhang Y; Smith RJH
    Front Immunol; 2022; 13():1073802. PubMed ID: 36846022
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Rare Variants in Complement Gene in C3 Glomerulopathy and Immunoglobulin-Mediated Membranoproliferative GN.
    Meuleman MS; Vieira-Martins P; El Sissy C; Audard V; Baudouin V; Bertrand D; Bridoux F; Louillet F; Dossier C; Esnault V; Jourde-Chiche N; Karras A; Morin MP; Provot F; Remy P; Ribes D; Rousset-Rouviere C; Servais A; Thervet E; Tricot L; Zaidan M; Wynckel A; Zuber J; Le Quintrec M; Frémeaux-Bacchi V; Chauvet S
    Clin J Am Soc Nephrol; 2023 Nov; 18(11):1435-1445. PubMed ID: 37615951
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Membranoproliferative glomerulonephritis with isolated C3 deposits: case report and literature review.
    Darouich S; Goucha R; Jaafoura MH; Zekri S; Kheder A; Ben Maiz H
    Ultrastruct Pathol; 2011 Feb; 35(1):42-6. PubMed ID: 21265634
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The role of complement in C3 glomerulopathy.
    Zipfel PF; Skerka C; Chen Q; Wiech T; Goodship T; Johnson S; Fremeaux-Bacchi V; Nester C; de Córdoba SR; Noris M; Pickering M; Smith R
    Mol Immunol; 2015 Sep; 67(1):21-30. PubMed ID: 25929733
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The MFHR1 Fusion Protein Is a Novel Synthetic Multitarget Complement Inhibitor with Therapeutic Potential.
    Michelfelder S; Fischer F; Wäldin A; Hörle KV; Pohl M; Parsons J; Reski R; Decker EL; Zipfel PF; Skerka C; Häffner K
    J Am Soc Nephrol; 2018 Apr; 29(4):1141-1153. PubMed ID: 29335241
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A novel CFHR1-CFHR5 hybrid leads to a familial dominant C3 glomerulopathy.
    Togarsimalemath SK; Sethi SK; Duggal R; Le Quintrec M; Jha P; Daniel R; Gonnet F; Bansal S; Roumenina LT; Fremeaux-Bacchi V; Kher V; Dragon-Durey MA
    Kidney Int; 2017 Oct; 92(4):876-887. PubMed ID: 28729035
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Factor H deficiency].
    Kanemitsu S; Hara T
    Ryoikibetsu Shokogun Shirizu; 2000; (32):218-20. PubMed ID: 11212697
    [No Abstract]   [Full Text] [Related]  

  • 59. Eculizumab for dense deposit disease and C3 glomerulonephritis.
    Bomback AS; Smith RJ; Barile GR; Zhang Y; Heher EC; Herlitz L; Stokes MB; Markowitz GS; D'Agati VD; Canetta PA; Radhakrishnan J; Appel GB
    Clin J Am Soc Nephrol; 2012 May; 7(5):748-56. PubMed ID: 22403278
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Discordant renal histopathologic findings and complement profiles in membranoproliferative glomerulonephritis type III.
    Meyers KE; Strife CF; Witzleben C; Kaplan BS
    Am J Kidney Dis; 1996 Dec; 28(6):804-10. PubMed ID: 8957031
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.